Completed Enrollment

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

J1O-MC-JZHD -

The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.

Trial Summary

Age Range
2 - 21 years
Conditions the trial is for
Neuroblastoma
What the trial is testing?
LY3295668 Erbumine, Topotecan, Cyclophosphamide
Could I receive a Placebo?
No
Enrollment Goal
71
Trial Dates
Jun 11, 2020 - Aug 2024
How long will I be in the trial?
Your participation in this trial could last up to 67 months, depending on your cancer type and how you and your tumor responds.
Trial Phase
I

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have relapsed/refractory neuroblastoma and have active disease in at least one site: bone, bone marrow or soft tissue.

  • Participants must be able to submit an archival sample of tissue

  • Participants must be able to swallow capsules

Participants Must Not:

  • Participants must not have had an allogeneic hematopoietic stem cell, bone marrow, or solid organ transplant

  • Participants must not have untreated tumor that has spread to the brain or spinal cord

  • Participants must not have a serious active disease other than neuroblastoma

  • Participants must not have a condition affecting absorption

  • Participants must not have had prior aurora kinase inhibitor exposure

  • Participants must not have a known allergy to the study treatment

  • Participants must not have symptomatic human immunodeficiency virus (HIV) infection or symptomatic activated/reactivated hepatitis A, B, or C

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources